Wow_老虎社区_美港股上老虎

2021-10-28

Wow

Merck Projects Billions in Sales of Covid Antiviral Molnupiravir<blockquote>默克预计新冠抗病毒药物莫努匹拉韦销售额达数十亿美元</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":854169852,"tweetId":"854169852","gmtCreate":1635428473107,"gmtModify":1635428513104,"author":{"id":4090156416829480,"idStr":"4090156416829480","authorId":4090156416829480,"authorIdStr":"4090156416829480","name":"yattreblif","avatar":"https://static.tigerbbs.com/0c09ba70f4dad4731020c2b9c484a4da","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Wow</body></html>","htmlText":"<html><head></head><body>Wow</body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/854169852","repostId":1152442963,"repostType":4,"repost":{"id":"1152442963","kind":"news","pubTimestamp":1635427505,"share":"https://www.laohunote.com/m/news/1152442963?lang=zh_CN&edition=full","pubTime":"2021-10-28 21:25","market":"us","language":"en","title":"Merck Projects Billions in Sales of Covid Antiviral Molnupiravir<blockquote>默克预计新冠抗病毒药物莫努匹拉韦销售额达数十亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1152442963","media":"Bloomberg","summary":"(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much ","content":"(Bloomberg) -- Merck &amp; Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.<blockquote>(彭博社）--据默克公司（Merck &amp; Co.）称，该公司备受关注的 Covid-19 抗病毒药物 molnupiravir 到 2022 年可能带来高达 70 亿美元的全球销售额。</blockquote> The figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December, Chief Financial Officer Caroline Litchfield said early Thursday on a conference call. She projected at least $5 billion in sales by the end of next year, provided it’s cleared.<blockquote>首席财务官 Caroline Litchfield 周四早些时候在电话会议上表示，如果实验性药物在 12 月获得批准，这一数字包括今年高达 10 亿美元的收入。她预计，如果获得批准，到明年年底，销售额将至少达到 50 亿美元。</blockquote> Molnupiravir has become one of the most highly anticipated coronavirus medications, as the pill is relatively cheap to make and easy to transport. Merck has taken steps to make sure that the drug will be distributed widely, including in low-income countries.<blockquote>莫努匹拉韦已成为最受期待的冠状病毒药物之一，因为这种药丸制造成本相对较低且易于运输。默克公司已采取措施确保该药物得到广泛分发，包括在低收入国家。</blockquote> The drugmaker raised its annual forecast as it reported quarterly profit and revenue that beat Wall Street’s expectations. Adjusted earnings for the year will be $5.65 to $5.70 a share, up from the earlier guidance of $5.47 to $5.57, the drugmaker said in a statement. Revenue will be $47.4 billion to $47.9 billion, compared with the earlier guidance that topped out at $47.4 billion. The projections don’t include potential molnupiravir sales.<blockquote>该制药商上调了年度预测，因为它公布的季度利润和收入超出了华尔街的预期。该制药商在一份声明中表示，今年调整后每股收益将为 5.65 美元至 5.70 美元，高于之前指导的 5.47 美元至 5.57 美元。收入将为 474 亿至 479 亿美元，而之前的指导峰值为 474 亿美元。这些预测不包括莫努匹拉韦的潜在销售额。</blockquote> Quarterly adjusted earnings were $1.75 a share, beating analysts’ average estimate by 20 cents, according to a statement. Revenue was $13.2 billion, compared with Wall Street expectations of $12.3 billion.<blockquote>根据一份声明，季度调整后每股收益为 1.75 美元，比分析师平均预期高出 20 美分。营收为 132 亿美元，而华尔街预期为 123 亿美元。</blockquote> The shares rose 2% in premarket U.S. trading.<blockquote>该股在美国盘前交易中上涨 2%。</blockquote> Merck and partner Ridgeback Biotherapeutics LP are seeking U.S. authorization of molnupiravir, their Covid antiviral. Merck said it plans to make at least 20 million treatment courses of the drug next year, on top of 10 million it expects to make by the end of 2021.<blockquote>默克公司和合作伙伴 Ridgeback Biotherapeutics LP 正在寻求美国对其 Covid 抗病毒药物 molnupiravir 的授权。默克公司表示，计划明年至少生产 2000 万个该药物治疗疗程，预计到 2021 年底将生产 1000 万个疗程。</blockquote> The drug may become one of Merck’s leading products. Merck’s blockbuster cancer drug Keytruda brought in more than $14 billion in sales last year, followed by the diabetes drug Januvia with around $5 billion and nearly $4 billion for HPV vaccine Gardasil.<blockquote>该药物可能成为默克公司的主导产品之一。默克公司的重磅癌症药物 Keytruda 去年的销售额超过 140 亿美元，其次是糖尿病药物 Januvia，销售额约为 50 亿美元，HPV 疫苗 Gardasil 销售额近 40 亿美元。</blockquote> Merck said vaccine revenue contributed to the third-quarter results. However, sales of its pneumococcal vaccine, Pneumovax 23, declined nearly 30%, “primarily driven by lower demand in the United States reflecting prioritization of the Covid-19 vaccine.”<blockquote>默克表示，疫苗收入对第三季度业绩做出了贡献。然而，其肺炎球菌疫苗 Pneumovax 23 的销售额下降了近 30%，“这主要是由于美国需求下降，反映出 Covid-19 疫苗的优先地位”。</blockquote> Sales of the papillomavirus vaccine Gardasil were $1.99 billion, topping estimates. Sales of blockbuster cancer drug Keytruda and the diabetes medications Januvia and Janumet also beat Wall Street projections. Animal health sales were $1.42 billion, in line with expectations.<blockquote>乳头瘤病毒疫苗 Gardasil 的销售额为 19.9 亿美元，超出预期。重磅抗癌药物 Keytruda 以及糖尿病药物 Januvia 和 Janumet 的销量也超出了华尔街的预测。动物保健销售额为14.2亿美元，符合预期。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Projects Billions in Sales of Covid Antiviral Molnupiravir<blockquote>默克预计新冠抗病毒药物莫努匹拉韦销售额达数十亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Projects Billions in Sales of Covid Antiviral Molnupiravir<blockquote>默克预计新冠抗病毒药物莫努匹拉韦销售额达数十亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-10-28 21:25\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Merck &amp; Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.<blockquote>(彭博社）--据默克公司（Merck &amp; Co.）称，该公司备受关注的 Covid-19 抗病毒药物 molnupiravir 到 2022 年可能带来高达 70 亿美元的全球销售额。</blockquote> The figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December, Chief Financial Officer Caroline Litchfield said early Thursday on a conference call. She projected at least $5 billion in sales by the end of next year, provided it’s cleared.<blockquote>首席财务官 Caroline Litchfield 周四早些时候在电话会议上表示，如果实验性药物在 12 月获得批准，这一数字包括今年高达 10 亿美元的收入。她预计，如果获得批准，到明年年底，销售额将至少达到 50 亿美元。</blockquote> Molnupiravir has become one of the most highly anticipated coronavirus medications, as the pill is relatively cheap to make and easy to transport. Merck has taken steps to make sure that the drug will be distributed widely, including in low-income countries.<blockquote>莫努匹拉韦已成为最受期待的冠状病毒药物之一，因为这种药丸制造成本相对较低且易于运输。默克公司已采取措施确保该药物得到广泛分发，包括在低收入国家。</blockquote> The drugmaker raised its annual forecast as it reported quarterly profit and revenue that beat Wall Street’s expectations. Adjusted earnings for the year will be $5.65 to $5.70 a share, up from the earlier guidance of $5.47 to $5.57, the drugmaker said in a statement. Revenue will be $47.4 billion to $47.9 billion, compared with the earlier guidance that topped out at $47.4 billion. The projections don’t include potential molnupiravir sales.<blockquote>该制药商上调了年度预测，因为它公布的季度利润和收入超出了华尔街的预期。该制药商在一份声明中表示，今年调整后每股收益将为 5.65 美元至 5.70 美元，高于之前指导的 5.47 美元至 5.57 美元。收入将为 474 亿至 479 亿美元，而之前的指导峰值为 474 亿美元。这些预测不包括莫努匹拉韦的潜在销售额。</blockquote> Quarterly adjusted earnings were $1.75 a share, beating analysts’ average estimate by 20 cents, according to a statement. Revenue was $13.2 billion, compared with Wall Street expectations of $12.3 billion.<blockquote>根据一份声明，季度调整后每股收益为 1.75 美元，比分析师平均预期高出 20 美分。营收为 132 亿美元，而华尔街预期为 123 亿美元。</blockquote> The shares rose 2% in premarket U.S. trading.<blockquote>该股在美国盘前交易中上涨 2%。</blockquote> Merck and partner Ridgeback Biotherapeutics LP are seeking U.S. authorization of molnupiravir, their Covid antiviral. Merck said it plans to make at least 20 million treatment courses of the drug next year, on top of 10 million it expects to make by the end of 2021.<blockquote>默克公司和合作伙伴 Ridgeback Biotherapeutics LP 正在寻求美国对其 Covid 抗病毒药物 molnupiravir 的授权。默克公司表示，计划明年至少生产 2000 万个该药物治疗疗程，预计到 2021 年底将生产 1000 万个疗程。</blockquote> The drug may become one of Merck’s leading products. Merck’s blockbuster cancer drug Keytruda brought in more than $14 billion in sales last year, followed by the diabetes drug Januvia with around $5 billion and nearly $4 billion for HPV vaccine Gardasil.<blockquote>该药物可能成为默克公司的主导产品之一。默克公司的重磅癌症药物 Keytruda 去年的销售额超过 140 亿美元，其次是糖尿病药物 Januvia，销售额约为 50 亿美元，HPV 疫苗 Gardasil 销售额近 40 亿美元。</blockquote> Merck said vaccine revenue contributed to the third-quarter results. However, sales of its pneumococcal vaccine, Pneumovax 23, declined nearly 30%, “primarily driven by lower demand in the United States reflecting prioritization of the Covid-19 vaccine.”<blockquote>默克表示，疫苗收入对第三季度业绩做出了贡献。然而，其肺炎球菌疫苗 Pneumovax 23 的销售额下降了近 30%，“这主要是由于美国需求下降，反映出 Covid-19 疫苗的优先地位”。</blockquote> Sales of the papillomavirus vaccine Gardasil were $1.99 billion, topping estimates. Sales of blockbuster cancer drug Keytruda and the diabetes medications Januvia and Janumet also beat Wall Street projections. Animal health sales were $1.42 billion, in line with expectations.<blockquote>乳头瘤病毒疫苗 Gardasil 的销售额为 19.9 亿美元，超出预期。重磅抗癌药物 Keytruda 以及糖尿病药物 Januvia 和 Janumet 的销量也超出了华尔街的预测。动物保健销售额为14.2亿美元，符合预期。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/merck-raises-annual-forecast-profit-104849738.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-raises-annual-forecast-profit-104849738.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152442963","content_text":"(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.\nThe figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December, Chief Financial Officer Caroline Litchfield said early Thursday on a conference call. She projected at least $5 billion in sales by the end of next year, provided it’s cleared.\nMolnupiravir has become one of the most highly anticipated coronavirus medications, as the pill is relatively cheap to make and easy to transport. Merck has taken steps to make sure that the drug will be distributed widely, including in low-income countries.\nThe drugmaker raised its annual forecast as it reported quarterly profit and revenue that beat Wall Street’s expectations. Adjusted earnings for the year will be $5.65 to $5.70 a share, up from the earlier guidance of $5.47 to $5.57, the drugmaker said in a statement. Revenue will be $47.4 billion to $47.9 billion, compared with the earlier guidance that topped out at $47.4 billion. The projections don’t include potential molnupiravir sales.\nQuarterly adjusted earnings were $1.75 a share, beating analysts’ average estimate by 20 cents, according to a statement. Revenue was $13.2 billion, compared with Wall Street expectations of $12.3 billion.\nThe shares rose 2% in premarket U.S. trading.\nMerck and partner Ridgeback Biotherapeutics LP are seeking U.S. authorization of molnupiravir, their Covid antiviral. Merck said it plans to make at least 20 million treatment courses of the drug next year, on top of 10 million it expects to make by the end of 2021.\nThe drug may become one of Merck’s leading products. Merck’s blockbuster cancer drug Keytruda brought in more than $14 billion in sales last year, followed by the diabetes drug Januvia with around $5 billion and nearly $4 billion for HPV vaccine Gardasil.\nMerck said vaccine revenue contributed to the third-quarter results. However, sales of its pneumococcal vaccine, Pneumovax 23, declined nearly 30%, “primarily driven by lower demand in the United States reflecting prioritization of the Covid-19 vaccine.”\nSales of the papillomavirus vaccine Gardasil were $1.99 billion, topping estimates. Sales of blockbuster cancer drug Keytruda and the diabetes medications Januvia and Janumet also beat Wall Street projections. Animal health sales were $1.42 billion, in line with expectations.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":744,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/854169852"}